August 29, 2011 -- Nycomed, a privately owned Swiss biopharma, said its recent acquisition of Guangdong Techpool Biopharma and a direct sales model in China boosted the company’s revenues in Q2. Asia-Pacific, Africa and Middle East saw revenues climb by 81%, though the company did not break out China sales separately. In November 2010, Nycomed announced it would spend $210 million to purchase a 51% stake in Techpool, a biologics company. More details....
